Exelixis | EXEL - Cost Of Sales


Exelixis reported $26.48M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
Agios Pharmaceuticals USD 1.88M 199K Dec/2025
Akebia Therapeutics USD 10.34M 441K Dec/2025
Amgen USD 1.79B 128M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
Bayer EUR 4.5B 194M Dec/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Cytokinetics USD 99.23M 13.32M Sep/2025
Eisai JPY 51.08B 5.56B Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
Exelixis USD 26.48M 7.91M Dec/2025
Genmab DKK 81M 23M Dec/2025
Glaxosmithkline GBP 3.47B 461.37M Dec/2025
Incyte USD 121.18M 22.18M Dec/2025
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
MacroGenics USD 10.12M 34.18M Dec/2025
Merck USD 3.32B 531M Dec/2025
Moderna USD 452M 245M Dec/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Novartis USD 3.54B 3M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Sanofi EUR 3.76B 344M Dec/2025
Takeda JPY 401.15B 184.07B Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
Xencor USD 61.66M 50.95M Jun/2025